Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
BIIB [NASD]
Biogen Idec Inc.
IndexS&P 500 P/E36.58 EPS (ttm)9.00 Insider Own0.10% Shs Outstand236.14M Perf Week1.81%
Market Cap77.75B Forward P/E20.41 EPS next Y16.13 Insider Trans-4.06% Shs Float235.91M Perf Month-3.89%
Income2.14B PEG1.83 EPS next Q3.45 Inst Own92.20% Short Float1.35% Perf Quarter3.02%
Sales8.34B P/S9.32 EPS this Y35.60% Inst Trans-0.42% Short Ratio2.86 Perf Half Y3.36%
Book/sh40.40 P/B8.15 EPS next Y23.19% ROA17.70% Target Price371.95 Perf Year32.77%
Cash/sh6.66 P/C49.42 EPS next 5Y20.00% ROE24.10% 52W Range221.07 - 358.89 Perf YTD17.77%
Dividend- P/FCF32.96 EPS past 5Y24.10% ROI20.70% 52W High-8.26% Beta1.23
Dividend %- Quick Ratio1.70 Sales past 5Y11.10% Gross Margin87.20% 52W Low48.93% ATR7.19
Employees6850 Current Ratio2.00 Sales Q/Q40.50% Oper. Margin35.80% RSI (14)45.32 Volatility2.42% 2.05%
OptionableYes Debt/Eq0.06 EPS Q/Q46.10% Profit Margin25.60% Rel Volume1.56 Prev Close329.99
ShortableYes LT Debt/Eq0.06 EarningsJul 23 BMO Payout0.00% Avg Volume1.11M Price329.24
Recom2.10 SMA20-1.56% SMA50-0.15% SMA2005.56% Volume1,741,592 Change-0.23%
19-Aug-14Resumed Stifel Buy $376
29-Jul-14Reiterated Argus Buy $360 → $385
24-Jul-14Reiterated UBS Neutral $330 → $354
09-Jul-14Reiterated RBC Capital Mkts Outperform $325 → $375
19-Mar-14Reiterated Stifel Buy $360 → $376
07-Mar-14Reiterated Barclays Overweight $325 → $352
03-Mar-14Reiterated Stifel Buy $330 → $360
30-Jan-14Reiterated UBS Neutral $300 → $310
30-Jan-14Reiterated Brean Capital Buy $293 → $377
30-Jan-14Reiterated Argus Buy $310 → $360
28-Jan-14Reiterated Deutsche Bank Buy $340 → $415
27-Jan-14Reiterated Canaccord Genuity Buy $291 → $355
16-Jan-14Reiterated Stifel Buy $296 → $321
10-Jan-14Reiterated Barclays Overweight $285 → $325
20-Dec-13Reiterated RBC Capital Mkts Outperform $275 → $325
12-Dec-13Reiterated Argus Buy $280 → $310
30-Oct-13Initiated FBR Capital Mkt Perform $259
29-Oct-13Reiterated Barclays Overweight $240 → $262
17-Jul-13Reiterated Barclays Overweight $220 → $240
09-May-13Reiterated MKM Partners Neutral $208 → $215
19-Sep-14 01:50PM  Is Merck KGaA on Track with its "Fit for 2018" Program? Zacks
06:43AM  Arena Pharmaceuticals, Inc. (ARNA) Jumps: Stock Rises 9.5% Zacks
18-Sep-14 04:10PM  Alnylam (ALNY) to File Clinical Trial Application for ALN-CC5 Zacks
10:52AM  2 Columbia Growth Funds Notch Impressive Three-Month Performance Benzinga
07:06AM  Repros Therapeutics (RPRX) Crumbles: Stock Falls by 10.5% Zacks
17-Sep-14 06:15PM  Merck Posts Positive Data on Osteoporosis Drug Odanacatib Zacks
16-Sep-14 07:41AM  Zacks Rank #1 Additions for Tuesday Zacks
15-Sep-14 04:50PM  Biogen/AbbVie Report Positive Data on MS Drug Zinbryta Zacks
02:55PM  Nasdaq Falls Hard, But Apple Resilient On iPhone Orders at Investor's Business Daily
01:04PM  3 Stocks Underperforming Today In The Drugs Industry at TheStreet
13-Sep-14 08:02AM  Gilead, Jazz, Salix Among Top 6 IBD 50 Drugmakers at Investor's Business Daily
12-Sep-14 04:30PM  Sanofi Reports Data on Multiple Sclerosis Drug Lemtrada Zacks
03:30PM  Biogen Reports Positive Two-Year Data on MS Drug Plegridy Zacks
07:30AM  Detailed Results from Biogen Idec and AbbVies Pivotal Phase 3 Decide Study Further Define the Efficacy and Safety Profile of ZINBRYTA (Daclizumab High-Yield Process) Business Wire
11-Sep-14 05:41PM  Medivation Eyes Blockbuster As Cancer Drug Gets An OK at Investor's Business Daily
02:46PM  Stocks Show Modest Losses; Biotechs Pressured Again at Investor's Business Daily
09:20AM  Short Sellers Remain Vigilant Against Biotechs at 24/7 Wall St.
08:17AM  Biogen Idec, Inc. Suddenly Struggling To Keep Up With The Biotech Joneses Benzinga
08:17AM  Biogen Idec Inc Suddenly Struggling To Keep Up With The Biotech Joneses Benzinga
07:30AM  PLEGRIDY (Peginterferon Beta-1a) Two-Year Data Confirm Maintenance of Efficacy and Safety in Multiple Sclerosis Patients Business Wire
07:30AM  New Data from ENDORSE Show Positive Results Continued over Five Years with TECFIDERA® (Dimethyl Fumarate) in a Wide Range of Multiple Sclerosis Patients Business Wire
01:00AM  Sanofi aims to grow Genzyme unit with new drugs and acquisitions Reuters
10-Sep-14 01:25PM  Stocks Turn Higher After Soft Start; U.S. Silica Jumps at Investor's Business Daily
11:58AM  ReceptosMS Drug Yields More Good Data; Stock Jumps at Investor's Business Daily
11:58AM  Receptos MS Drug Yields More Good Data; Stock Jumps at Investor's Business Daily
10:17AM  Biotech Stock Roundup: AbbVie Ties Up with Infinity, Keryx Slips on FDA Approval Zacks
07:00AM  New International Survey Finds MS Patients and Neurologists View Communication Positively, Yet Struggle to Discuss Key MS Symptoms Business Wire
09-Sep-14 01:04PM  3 Stocks Pushing The Drugs Industry Lower at TheStreet
08-Sep-14 08:48AM  J.P. Morgan Biotech Analyst Meacham Exits for New Barclays Gig at TheStreet
05-Sep-14 12:54PM  [video] 3 Biotech picks: Gilead, Biogen & Celgene at CNBC
12:04PM  Indexes Trim Losses But Remain Lower At Midday at Investor's Business Daily
04-Sep-14 11:01AM  Celgene: Good Data But What About the Patent Challenges? at Barrons.com
03-Sep-14 08:00AM  Biogen Idec Data at Joint ACTRIMS-ECTRIMS Meeting Highlight Robust Multiple Sclerosis Portfolio and Commitment to Advancing Patient Care Business Wire
02-Sep-14 07:36PM  Biotech Helps Drive Broad Market at Investor's Business Daily
04:01PM  Biogen Idec to Present at the Morgan Stanley Global Healthcare Conference 2014 Business Wire
09:56AM  This tiny biotech company takes the real ice bucket challenge at MarketWatch
09:16AM  This tiny biotech company takes the real ice bucket challenge at MarketWatch
06:10AM  Biotech companies take the real ice bucket challenge at MarketWatch
27-Aug-14 05:20PM  Biogen's Eloctate Approved in Canada for Hemophilia A Zacks
11:04AM  Should you buy ISIS? No, not that one at CNNMoney.com
10:25AM  Rising Short Interest in Biotech Stocks 24/7 Wall St.
26-Aug-14 05:55PM  Celgene, Gilead Lead Big Biotech Stock Movers at Investor's Business Daily
04:01PM  Biogen Idec in Panel at the Citi 9th Annual Biotech Conference Business Wire
02:38PM  Celgene, Gilead Lead Big Biotech Stock Movers at Investor's Business Daily
08:00AM  Health Canada Approves Eloctate, the First Therapy to Extend the Interval Between Prophylactic Infusions in Hemophilia A PR Newswire
08:00AM  Health Canada Approves Eloctate, the First Therapy to Extend the Interval Between Prophylactic Infusions in Hemophilia A CNW Group
08:00AM  Donald Johns Joins Biogen Idec to Lead ALS Innovation Hub Business Wire
25-Aug-14 02:54PM  Stocks Hold Decent Gains; InterMune Deal Sparks Biotechs at Investor's Business Daily
22-Aug-14 06:37PM  Majority Of IBD 50 Firms Strong On Sponsorship at Investor's Business Daily
04:35PM  Data on Celgene's Revlimid Published in Oncology Journal Zacks
21-Aug-14 03:47PM  5 companies that will benefit from ALS awareness at MarketWatch
03:20PM  Dell CIO Andi Karaboutis Leaving for Biotech Firm Biogen at The Wall Street Journal
07:53AM  The Zacks Analyst Blog Highlights: Achillion Pharmaceuticals, Gilead Sciences, Amgen, Roche and Biogen Zacks
07:00AM  Biogen Idec Names Adriana Karaboutis EVP, Technology and Business Solutions Business Wire
20-Aug-14 02:31PM  What Investors Gain from Large, Mid & Small-Cap Growth Funds Zacks
08:40AM  6 Biotech Stocks to Buy Now With Up to 100% Upside Potential 24/7 Wall St.
19-Aug-14 02:31PM  [video] Hottest stories not always hottest stock: Greenberg at CNBC
12:39PM  Want a better return than Apple or Google? at CNBC
12:20PM  Biogen Strengthens MS Portfolio with Plegridy FDA Approval Zacks
18-Aug-14 11:44AM  Why Biogen Idec (BIIB) Stock Is Gaining Today at TheStreet
11:19AM  Biogen Idec: Drug Approval Offers 'Underappreciated Earnings Upside," Morgan Stanley Says at Barrons.com
09:16AM  [video] Cramer: Market about Russia-Ukraine at CNBC
15-Aug-14 07:27PM  FDA approves Biogen's MS drug Plegridy AP
06:49PM  Biogen wins U.S. approval of long acting multiple sclerosis drug Reuters
06:36PM  FDA approves Biogen Idec's multiple sclerosis drug Reuters
06:32PM  Biogen Idecs PLEGRIDY(Peginterferon Beta-1a) Approved in the US for the Treatment of Multiple Sclerosis Business Wire
09:49AM  Today's Momo Momentum Stock Is Biogen Idec (BIIB) at TheStreet
07:36AM  [video] ALS stunned by millions of dollars at CNBC
07:32AM  [video] What is ALS? at CNBC
14-Aug-14 06:36PM  Perrigo Regains Some Lost Ground On Fiscal Q4 Beat at Investor's Business Daily
01:15PM  Perrigo Beats on Q4 Earnings and Sales, Provides Guidance Zacks
12:34PM  Biotech, Social Media Stocks Are Less Frothy Than Janet Yellen Thinks at TheStreet
11:02AM  Perrigo Q4 Beats Estimates, But Guidance Misses at Investor's Business Daily
13-Aug-14 06:08PM  Cramer: Is Street preparing for the worst? at CNBC
04:30PM  Stocks close higher for the third time in four days on tech boost at CNBC
02:29PM  Stocks higher on biotech, transports at CNBC
02:07PM  Stocks higher on biotech, transports; Nasdaq up 1% at CNBC
01:21PM  Stocks higher on biotech, transports at CNBC
09:50AM  [video] CNBC ice bucket brigade at CNBC
09:44AM  Biogen...and CNBC take the ice bucket challenge at CNBC
12-Aug-14 07:16PM  Top Large-Cap Growth Fund Owns Biogen, Facebook at Investor's Business Daily
01:25PM  Biogen...and CNBC take the ice bucket challenge at CNBC
01:24PM  [video] Costolo accepts CNBC's ice bucket challenge at CNBC
12:57PM  [video] CNBC's Wapner accepts ice bucket challenge at CNBC
12:35PM  [video] Biogen accepts ice bucket challenge at CNBC
08:54AM  [video] Ice Bucket Challenge for ALS at CNBC
08-Aug-14 10:26AM  Howard Zauberman, the President and CEO of Vision-Sciences, Inc. (VSCI), Interviews with The Wall Street Transcript Wall Street Transcript
07:00AM  #PreMarket Primer: Friday, August 8: U.S. To Begin Airstrikes In Iraq Benzinga
07-Aug-14 08:10AM  Isis Pharmaceuticals Posts Narrower-Than-Expected Q2 Loss Zacks
06-Aug-14 01:23PM  Celgene: Five Reasons to Be Bullish at Barrons.com
05-Aug-14 02:17PM  [video] Enormous hype about Ebola: Doctor at CNBC
01:30PM  [video] Risk & compassionate use drug requests at CNBC
08:00AM  Regulus Enters Into New Collaboration Agreement with Biogen Idec to Identify microRNA Biomarkers in Multiple Sclerosis PR Newswire
04-Aug-14 08:20AM  Acorda Beats on Q2 Earnings & Revenues, Maintains View Zacks
01-Aug-14 12:01PM  Wall Street Transcript Interview with Charles R. Kummeth, the President and CEO of Bio-Techne (TECH) Wall Street Transcript
31-Jul-14 09:33AM  Stock Market News for July 31, 2014 Zacks
08:26AM  The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene Zacks
08:10AM  Increased Earnings Estimates Seen for Biogen Idec (BIIB): Can It Move Higher? Zacks
30-Jul-14 06:00PM  [video] Cramer's 5 steps of the stock market at CNBC
01:04PM  BIOGEN IDEC INC. Financials EDGAR Online Financials
Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of multiple sclerosis (MS), neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. It provides AVONEX to treat relapsing MS; TYSABRI to treat relapsing forms of MS and Crohn's disease; RITUXAN for treating relapsed or refractory, follicular, CD20-positive, and B-cell Non-Hodgkin's lymphoma (NHL); FUMADERM to treat severe plaque psoriasis in adult patients; FAMPYRA, an oral compound for the improvement of walking in adult patients with MS; TECFIDERA for the treatment of MS; and GAZYVA, an injection for intravenous infusion that treats an untreated chronic lymphocytic leukemia. The company's products that completed Phase III clinical trials comprise ELOCTATE and ALPROLIX, an inherited disorder that inhibits blood coagulations; and Peginterferon beta-1a to prolong the effects and reduce the dosing frequency of interferon beta-1a. Its products under Phase III clinical trials consist of Daclizumab, a monoclonal antibody in relapsing MS; TYSABRI for secondary progressive MS; and GA101, a monoclonal antibody for chronic lymphocytic leukemia and NHL. The company's Phase II clinical trial products include Anti-LINGO for optic neuritis; STX-100 for idiopathic pulmonary fibrosis; Neublastin for neuropathic pain; and ANTI-TWAEK for lupus nephritis. Its Phase I clinical trial products comprise BIIB037 for Alzheimer's disease; BIIB037 for MS; and Anti-CD40 Ligand for general lupus, as well as Phase 1b/2a clinical trial products include ISIS-SMNRx for spinal muscular atrophy. Biogen Idec Inc. has collaboration agreements with Genentech, Inc.; Acorda Therapeutics, Inc.; Sangamo BioSciences; and Swedish Orphan Biovitrum AB. The company was formerly known as IDEC Pharmaceuticals Corporation and changed its name to Biogen Idec Inc. in November 2003. Biogen Idec Inc. was founded in 1985 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SCANGOS GEORGE AChief Executive OfficerSep 02Sale345.471,128389,69020,240Sep 04 04:15 PM
SCANGOS GEORGE AChief Executive OfficerAug 01Sale332.931,128375,54521,368Aug 04 04:43 PM
SCANGOS GEORGE AChief Executive OfficerJul 16Sale312.3712,3163,847,14922,496Jul 18 05:59 PM
SCANGOS GEORGE AChief Executive OfficerJul 15Option Exercise0.0021,339044,874Jul 17 04:45 PM
Posner Brian SDirectorJun 20Sale315.00605190,5756,000Jun 23 04:37 PM
Posner Brian SDirectorJun 13Sale310.50700217,3506,605Jun 16 04:37 PM
SCANGOS GEORGE AChief Executive OfficerJun 02Sale318.93484154,36223,535Jun 03 04:29 PM
Holtzman Steven HEVP Corporate DevelopmentMay 19Sale289.151,221353,0525,749May 20 04:16 PM
COVINO GREGORY FVP, Chief Accounting OfficerMay 01Option Exercise286.7534799,5021,029May 02 04:20 PM
SCANGOS GEORGE AChief Executive OfficerMay 01Sale285.562,123606,24124,019May 02 04:22 PM
Holtzman Steven HEVP Corporate DevelopmentApr 17Sale291.001,221355,3116,970Apr 21 05:07 PM
Artavanis-Tsakonas SpyridonSVP, Chief Scientific OfficerApr 02Option Exercise0.0097502,677Apr 03 04:27 PM
SCANGOS GEORGE AChief Executive OfficerApr 01Sale308.422,123654,77626,142Apr 02 04:16 PM
Posner Brian SDirectorMar 31Sale296.763,000890,2756,435Apr 01 04:15 PM
DORSA CAROLINEDirectorMar 20Option Exercise53.6410,000536,40024,468Mar 21 04:17 PM
DORSA CAROLINEDirectorMar 20Sale348.8810,0003,488,81314,468Mar 21 04:17 PM
WILLIAMS DOUGLAS EEVP Research & DevelopmentMar 19Sale352.293,5051,234,7767,976Mar 21 04:15 PM
Holtzman Steven HEVP Corporate DevelopmentMar 17Sale334.831,221408,8278,191Mar 18 05:08 PM
Kingsley Stuart AEVP, Global Comm. OperationsMar 11Sale336.838,4282,838,7663,511Mar 12 07:15 PM
SCANGOS GEORGE AChief Executive OfficerMar 10Sale333.7726,1248,719,37828,265Mar 12 07:20 PM
LEAMING NANCYDirectorMar 10Sale327.652,000655,3007,660Mar 12 07:16 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerMar 04Sale342.583,1711,086,32115,407Mar 05 03:12 PM
SCANGOS GEORGE AChief Executive OfficerMar 03Sale335.792,942987,89454,389Mar 04 03:19 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 26Sale342.171,048358,59421,407Feb 27 04:19 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 23Option Exercise0.001,988023,395Feb 25 02:21 PM
Cox JohnEVP Pharmaceutical Oper & TechFeb 23Option Exercise0.002,598026,706Feb 25 02:17 PM
Clancy Paul JExecutive VP and CFOFeb 23Option Exercise0.004,280017,473Feb 25 02:11 PM
ALEXANDER SUSAN HEVP, Chief Legal OfficerFeb 23Option Exercise0.003,821023,930Feb 25 02:07 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 18Sale327.901,222400,6949,412Feb 19 04:23 PM
DiPietro KennethEVP Human ResourcesFeb 13Sale316.811,290408,6850Feb 14 04:36 PM
SCANGOS GEORGE AChief Executive OfficerFeb 13Sale316.81486153,97057,331Feb 14 04:37 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 13Sale316.42425134,47821,407Feb 14 04:42 PM
Kingsley Stuart AEVP, Global Comm. OperationsFeb 12Option Exercise0.002,246012,998Feb 14 04:33 PM
WILLIAMS DOUGLAS EEVP Research & DevelopmentFeb 12Option Exercise0.003,573013,166Feb 14 04:48 PM
Clancy Paul JExecutive VP and CFOFeb 12Option Exercise0.002,807014,517Feb 14 04:46 PM
ALEXANDER SUSAN HEVP, Chief Legal OfficerFeb 12Option Exercise0.002,142021,119Feb 14 04:43 PM
Artavanis-Tsakonas SpyridonSVP, Chief Scientific OfficerFeb 12Option Exercise0.0071401,941Feb 14 04:45 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 12Option Exercise0.00792014,459Feb 14 04:42 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 12Option Exercise0.002,142011,644Feb 14 04:39 PM
SCANGOS GEORGE AChief Executive OfficerFeb 12Option Exercise0.009,189062,150Feb 14 04:37 PM
DiPietro KennethEVP Human ResourcesFeb 12Option Exercise0.002,24602,246Feb 14 04:36 PM
COVINO GREGORY FVP, Chief Accounting OfficerFeb 12Option Exercise0.003150690Feb 14 04:38 PM
Cox JohnEVP Pharmaceutical Oper & TechFeb 12Option Exercise0.002,246025,167Feb 14 04:34 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 11Sale314.312,085655,33613,667Feb 12 05:03 PM
SCANGOS GEORGE AChief Executive OfficerFeb 11Sale314.312,456771,94552,961Feb 12 05:00 PM
SCANGOS GEORGE AChief Executive OfficerFeb 10Option Exercise0.0018,833064,297Feb 11 07:55 PM
Clancy Paul JExecutive VP and CFOFeb 09Option Exercise0.004,691013,922Feb 11 07:49 PM
SCANGOS GEORGE AChief Executive OfficerFeb 09Option Exercise0.0011,270050,314Feb 11 07:55 PM
Kingsley Stuart AEVP, Global Comm. OperationsFeb 09Option Exercise0.001,824011,613Feb 11 07:52 PM
ALEXANDER SUSAN HEVP, Chief Legal OfficerFeb 09Option Exercise0.003,909020,723Feb 11 06:07 PM
Cox JohnEVP Pharmaceutical Oper & TechFeb 09Option Exercise0.004,691025,133Feb 11 06:07 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 09Option Exercise0.001,824016,346Feb 11 07:43 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 08Option Exercise0.001,277014,944Feb 11 07:43 PM
Cox JohnEVP Pharmaceutical Oper & TechFeb 08Option Exercise0.004,023021,883Feb 11 06:07 PM
ALEXANDER SUSAN HEVP, Chief Legal OfficerFeb 08Option Exercise0.002,498017,633Feb 11 06:07 PM
Kingsley Stuart AEVP, Global Comm. OperationsFeb 08Option Exercise0.002,636011,032Feb 11 07:52 PM
Clancy Paul JExecutive VP and CFOFeb 08Option Exercise0.003,191010,278Feb 11 07:49 PM
WILLIAMS DOUGLAS EEVP Research & DevelopmentFeb 08Option Exercise0.003,468011,229Feb 11 07:47 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 08Option Exercise0.002,705010,778Feb 11 07:45 PM
DiPietro KennethEVP Human ResourcesFeb 04Sale299.011,655494,8620Feb 05 04:36 PM
DiPietro KennethEVP Human ResourcesFeb 01Option Exercise0.002,46302,463Feb 03 05:29 PM
WILLIAMS DOUGLAS EEVP Research & DevelopmentFeb 01Option Exercise0.005,15909,730Feb 03 05:25 PM
Kingsley Stuart AEVP, Global Comm. OperationsFeb 01Option Exercise0.004,586010,097Feb 03 05:20 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 01Option Exercise0.005,159010,044Feb 03 05:15 PM
Rowinsky Eric KDirectorJan 21Sale310.092,020626,38210,440Jan 22 04:49 PM
YOUNG WILLIAMDirectorJan 08Sale285.1115,0004,276,59018,509Jan 09 04:24 PM
PANGIA ROBERT WDirectorJan 06Option Exercise47.556,250297,18820,253Jan 07 12:22 PM
PANGIA ROBERT WDirectorJan 06Sale278.036,2501,737,68814,003Jan 07 12:22 PM
SHERWIN STEPHEN ADirectorJan 02Option Exercise59.825,500329,0109,460Jan 06 11:19 AM
SHERWIN STEPHEN ADirectorJan 02Sale279.285,5001,536,0593,960Jan 06 11:19 AM
Sandrock AlfredGrp SVP, Chief Medical OfficerDec 04Sale285.90439125,51013,667Dec 05 02:53 PM
SCHENK LYNNDirectorDec 02Sale291.711,000291,7104,100Dec 02 03:28 PM
Pawlicki RaymondSVP, Chief Information OfficerNov 22Option Exercise49.954,000199,80012,710Nov 25 02:11 PM
Pawlicki RaymondSVP, Chief Information OfficerNov 22Sale288.004,0001,152,0008,710Nov 25 02:11 PM
SCHENK LYNNDirectorNov 01Sale245.001,000245,0005,100Nov 05 12:18 PM
SCANGOS GEORGE AChief Executive OfficerNov 01Sale245.572,239549,83139,044Nov 05 12:13 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerOct 22Option Exercise60.5615,030910,21729,530Oct 23 05:03 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerOct 22Sale250.1115,0303,759,12314,500Oct 23 05:03 PM
SCHENK LYNNDirectorOct 01Sale242.851,000242,8506,100Oct 02 05:09 PM
SCANGOS GEORGE AChief Executive OfficerOct 01Sale242.852,239543,74141,283Oct 02 04:35 PM
DiPietro KennethEVP Human ResourcesSep 30Sale242.001,440348,4800Oct 02 01:36 PM